Indoco Remedies shares gain on final USFDA approval for Pregabalin capsules

The share touched a 52-week high of Rs 416.95 and a 52-week low of Rs 308.80 on January 1, 2024, and October 26, 2023, respectively.

MONEYCONTROL NEWS MAY 22, 2024 / 10:07 AM IST

Indoco Remedies share price gained in the early trade on May 22 after the company received final US Food and Drug Administration (US FDA) approval for Abbreviated New Drug Application (ANDA) for Pregabalin capsules.

At 09:26 am, Indoco Remedies was quoting at Rs 317.05, up Rs 1.85, or 0.59 percent, on the BSE.

The company announced the receipt of final approval from the USFDA for for Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, which is a generic equivalent of the Reference Listed Drug, Lyrica Capsules.

This product will be manufactured at the company's manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa, India.

Pregabalin is used for Neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injury, Postherpetic neuralgia and Fibromyalgia.